...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>ANZ journal of surgery >Safety of single‐incision laparoscopic cholecystectomy for acute cholecystitis
【24h】

Safety of single‐incision laparoscopic cholecystectomy for acute cholecystitis

机译：单切口腹腔镜胆囊切除术治疗急性胆囊炎

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Single‐incision laparoscopic cholecystectomy ( SILC ) is a common procedure performed worldwide. In this study, we evaluated the safety and efficacy of SILC for acute cholecystitis. Methods Patients who underwent SILC between September 2012 and December 2016 were retrospectively enrolled and divided into acute and chronic groups. Demographic, operative and outcome data were obtained by reviewing medical records, physical examination and telephone follow‐up. Results In total, 1435 patients were included in this study: 220 (15.3%) in the acute group and 1215 (84.7%) in the chronic group. The mean operative time was longer in the acute group than in the chronic group (44.7 ± 21.6 versus 32.8 ± 9.8 min; P 0.001). Insertion of additional ports was performed in 17 patients: six in the acute group and 11 in the chronic group. Conversion to abdominal laparotomy was performed in eight patients: one in the acute group and seven in the chronic group. The mean post‐operative hospital stay was 31.7 ± 20.4 h in the acute group and 27.7 ± 13.7 h in the chronic group. The complication rate was similar between the acute ( n = 8, 3.6%) and chronic ( n = 33, 2.7%) groups. Conclusion SILC does not increase the complication rate and is a safe and feasible technique for both chronic and acute cholecystitis.
机译：背景技术单切口腹腔镜胆囊切除术（Silc）是全球性的常用程序。在这项研究中，我们评估了Silc用于急性胆囊炎的安全性和功效。方法回顾性注册和分为急性和慢性群体的患者在2012年9月和2016年12月之间接受SILC的患者。通过审查医疗记录，体检和电话随访获得人口，手术和结果数据。结果总共包括1435名患者在本研究中包含：急性基团中的220（15.3％），慢性基团中的1215（84.7％）。急性群中的平均手术时间比慢性基团更长（44.7±21.6与32.8±9.8分钟; P <0.001）。在17例患者中进行额外端口的插入：急性群中的六个，慢性基团11例。在八名患者中进行腹部剖腹手术转换：急性组中的一种，慢性组中的七。急性术后医院住院的平均术后住院时间为31.7±20.4小时，在慢性组中的27.7±13.7小时。在急性（n = 8,3.6％）和慢性（n = 33,2.7％）组之间的并发症率类似。结论Silc不会增加并发症率，是慢性和急性胆囊炎的安全和可行的技术。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号